What We're Reading: Page 69
Industry reads hand-picked by our editors
Jan 16, 2024
-
The Wall Street Journal
Medicare Patients on Pricey Drugs Are Saving Big This Year
-
CNBC
Cancer drugs: Renewed interest in ADCs will continue in 2024
-
Reuters
Trade union opposes possible split-up of Germany’s Bayer
-
AP News
Vivek Ramaswamy suspends his 2024 Republican presidential bid and endorses rival Donald Trump
Jan 12, 2024
-
The Wall Street Journal
Cancer Is Striking More Young People, and Doctors Are Alarmed and Baffled
-
MIT Technology Review
The innovation that gets an Alzheimer’s drug through the blood-brain barrier
-
LifeSciVC
Biotech Venture Ecosystem: Quick Health Check
Jan 11, 2024
Jan 10, 2024
Jan 09, 2024
-
Bloomberg
Bayer Pharma Head Sees Brighter Future With Deals, New Drugs
-
Nature Medicine
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
-
The New York Times
F.D.A. Warned of Mental Side Effects from Asthma Drug, Singulair. Few Were Told.
-
Endpoints News
Exelixis cuts 175 staffers to prioritize late-stage drug development
Jan 08, 2024
-
The Wall Street Journal
Boston Scientific To Acquire Axonics For About $3.7 Billion
-
Bloomberg Law
Sarepta Exes Out RegenxBio Patent in Delaware Federal Lawsuit
-
Retuers
Bayer’s menopausal relief drug succeeds in late-stage trial
-
Fierce Pharma
As CDMOs come off pandemic’s highs and lows, employment and funding hitches persist
Previous
